Eye care practitioners in Australia have access to a new treatment modality for myopia with the listing of Eyerising International’s Repeated Low-Level Red-Light (RLRL) therapy device by the Australian Therapeutic Goods Administration (ARTG No: 41275).
Based on the work of Professor Mingguang He, a world-renowned ophthalmologist and myopia expert, the technology is indicated for the treatment of myopia at home.
Using patented technology to deliver RLRL therapy, Eyerising states that its myopia management device gently stimulates blood flow in the ocular fundus to alleviate sclera hypoxia and control the axial lengthening that causes myopia.
The device is already in widespread use overseas across populations including students, with distribution licenses finalised and first sales having occurred in Japan, New Zealand, and Turkey. The company is targeting a minimum roll out in 10 countries by the end of December.
Austrade has actively assisted Eyerising International Pty Ltd in cementing its distribution arrangements and continues to help the worldwide rollout.
To find out more, visit www.eyerisinginternational.com.
